VISEN Pharma trims outstanding share count with additional on-market repurchase

Bulletin Express06-08

VISEN Pharmaceuticals executed a further share buyback on 8 June 2026, repurchasing 5,700 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HKD 20.40 to HKD 20.74. The transaction cost totalled HKD 0.12 million.

Following the trade, the company’s issued share capital (excluding treasury shares) declined by 0.005 % to 113.83 million shares, while treasury shares increased to 97,400. The total share count, including treasury shares, remained unchanged at 113.93 million.

The latest purchase brings cumulative buybacks under the mandate approved on 27 June 2025 to 97,400 shares, equivalent to 0.09 % of the shares outstanding on the mandate date. VISEN Pharma is authorised to repurchase up to 11.39 million shares under the existing mandate and is subject to a 30-day moratorium—lasting until 8 July 2026—on issuing new shares or selling treasury shares following this repurchase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155588535?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 18:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155588535","market":"us","top_or_hot":-1,"title":"VISEN Pharma trims outstanding share count with additional on-market repurchase","media":"Bulletin Express","content":"<p>VISEN Pharmaceuticals executed a further share buyback on 8 June 2026, repurchasing 5,700 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HKD 20.40 to HKD 20.74. The transaction cost totalled HKD 0.12 million.</p>\n<p>Following the trade, the company’s issued share capital (excluding treasury shares) declined by 0.005 % to 113.83 million shares, while treasury shares increased to 97,400. The total share count, including treasury shares, remained unchanged at 113.93 million.</p>\n<p>The latest purchase brings cumulative buybacks under the mandate approved on 27 June 2025 to 97,400 shares, equivalent to 0.09 % of the shares outstanding on the mandate date. VISEN Pharma is authorised to repurchase up to 11.39 million shares under the existing mandate and is subject to a 30-day moratorium—lasting until 8 July 2026—on issuing new shares or selling treasury shares following this repurchase.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN Pharma trims outstanding share count with additional on-market repurchase</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN Pharma trims outstanding share count with additional on-market repurchase\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-08 18:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN Pharmaceuticals executed a further share buyback on 8 June 2026, repurchasing 5,700 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HKD 20.40 to HKD 20.74. The transaction cost totalled HKD 0.12 million.</p>\n<p>Following the trade, the company’s issued share capital (excluding treasury shares) declined by 0.005 % to 113.83 million shares, while treasury shares increased to 97,400. The total share count, including treasury shares, remained unchanged at 113.93 million.</p>\n<p>The latest purchase brings cumulative buybacks under the mandate approved on 27 June 2025 to 97,400 shares, equivalent to 0.09 % of the shares outstanding on the mandate date. VISEN Pharma is authorised to repurchase up to 11.39 million shares under the existing mandate and is subject to a 30-day moratorium—lasting until 8 July 2026—on issuing new shares or selling treasury shares following this repurchase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02561","symbol_name":"维昇药业-B","start_time":0,"source_url":"","article_id":"1155588535","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155588535","pubTimestamp":1780915482,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"VISEN Pharmaceuticals executed a further share buyback on 8 June 2026, repurchasing 5,700 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HKD 20.40 to HKD 20.74. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02561":"维昇药业-B"},"translate_title":"VISEN Pharma通过额外的市场回购削减流通股数量","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02561":1},"content_text":"VISEN Pharmaceuticals executed a further share buyback on 8 June 2026, repurchasing 5,700 ordinary shares on the Hong Kong Stock Exchange at prices ranging from HKD 20.40 to HKD 20.74. The transaction cost totalled HKD 0.12 million.\nFollowing the trade, the company’s issued share capital (excluding treasury shares) declined by 0.005 % to 113.83 million shares, while treasury shares increased to 97,400. The total share count, including treasury shares, remained unchanged at 113.93 million.\nThe latest purchase brings cumulative buybacks under the mandate approved on 27 June 2025 to 97,400 shares, equivalent to 0.09 % of the shares outstanding on the mandate date. VISEN Pharma is authorised to repurchase up to 11.39 million shares under the existing mandate and is subject to a 30-day moratorium—lasting until 8 July 2026—on issuing new shares or selling treasury shares following this repurchase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155588535","isCrawlerRequest":true}